Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

NEXT STORY
GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia
PREV STORY
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

author_avatar
NASDAQ Market News

Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

author_avatar
NASDAQ Market News